Canadian and European Patents Granted for Medical Enzymes lead product GlutaDON®

(PresseBox) (Berlin,, ) Medical Enzymes AG announced that it has received notice from the Canadian as well as from the European Patent Office that its Patent Application “Genetically Engineered Glutaminase and its Use in Antiviral and Anticancer Therapy” has been granted under Publication number CA 2149922 and EP 0692029. This patent addresses the DNA sequences of the enzyme Glutaminase, and the use thereof.

Furthermore Medical Enzymes AG has received notice from the European Patent Office that its Patent Application “Combined pharmaceutical preparations for the treatment of cancer, containing glutaminase and antineoplastic anthraciyclines or platinium compounds” has been granted under Publication number EP 1633394.

Glutaminase is the key enzyme concerning the mode of action of GlutaDON®. GlutaDON® is the lead product of Medical Enzymes AG for cancer treatment and has been successfully tested in clinical studies. "This is an important patent granted in Canada and Europe" said Dr. Michael Bausch, CEO of Medical Enzymes. "Our worldwide Intellectual property strategy has been successful and we are pleased to announce such an important patent for our lead product" Marc Voigt, CFO/CBO of Medical Enzymes added.

- About GlutaDON® -
GlutaDON® consists of a synthetic small molecule (DON) and the enzyme PEGylated Glutaminase, which could also be combined with other chemotherapeutics. GlutaDON® is the most advanced product in Medical Enzymes discovery and development program. GlutaDON® has been proven to be effective in numerous animal disease models for different cancer cell lines. The data of a clinical multi center phase I/IIa-Study is currently being evaluated. In the clinical development program, it has been shown to be well tolerated, safe administered with first encouraging signs of efficacy.

Kontakt

New Medical Enzymes AG
Fasanenstrasse 61
D-10719 Berlin
Social Media